Request Demo
Last update 13 Sep 2025
Anti-cd7 CARNK cell therapy (PersonGen Biomedicine)
Last update 13 Sep 2025
Overview
Basic Info
Drug Type CAR-NK |
Synonyms antiCD7 CARpNK cell therapy, CARpNK Cell immunotherapy |
Target |
Action inhibitors |
Mechanism CD7 inhibitors(T-cell antigen CD7 inhibitors), Gene transference(Gene transference), Natural killer cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with Anti-cd7 CARNK cell therapy (PersonGen Biomedicine)NCT02742727
Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma
100 Clinical Results associated with Anti-cd7 CARNK cell therapy (PersonGen Biomedicine)
Login to view more data
100 Translational Medicine associated with Anti-cd7 CARNK cell therapy (PersonGen Biomedicine)
Login to view more data
100 Patents (Medical) associated with Anti-cd7 CARNK cell therapy (PersonGen Biomedicine)
Login to view more data
100 Deals associated with Anti-cd7 CARNK cell therapy (PersonGen Biomedicine)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| CD7 Positive Acute Myeloid Leukemia | Phase 2 | China | 01 Mar 2016 | |
| CD7 Positive Leukemia | Phase 2 | China | 01 Mar 2016 | |
| Enteropathy-Associated T-Cell Lymphoma | Phase 2 | China | 01 Mar 2016 | |
| Extranodal NK-T-Cell Lymphoma | Phase 2 | China | 01 Mar 2016 | |
| hepatosplenic T-cell lymphoma | Phase 2 | China | 01 Mar 2016 | |
| Immunoblastic Lymphadenopathy | Phase 2 | China | 01 Mar 2016 | |
| Large Granular Lymphocytic Leukemia | Phase 2 | China | 01 Mar 2016 | |
| Peripheral T-Cell Lymphoma | Phase 2 | China | 01 Mar 2016 | |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Phase 2 | China | 01 Mar 2016 | |
| T-Cell Prolymphocytic Leukemia | Phase 2 | China | 01 Mar 2016 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free